Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ARRY-424704
AZD8330 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| AZD8330 | DRUG | oral tablet |
Inclusion Criteria: * Cancer which is refractory to standard therapies, or no therapies exist; Exclusion Criteria: * Participated in radiotherapy, biological or chemotherapy within 21 days prior to study start; * Hasn't participated in investigation drug study within 30 days; * Brain metastases/s...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
AZD8330 is an investigational small molecule drug developed by AstraZeneca for the treatment of cancer. It was studied in a Phase 1 clinical trial in patients with advanced malignancies. It is not approved for any indication and remains in clinical development.
AZD8330 was evaluated for use in cancer, specifically in patients with advanced malignancies. Its only clinical trial enrolled 83 patients with cancer. The drug is investigational and has not been approved for any cancer treatment.
AZD8330 targets MAP2K1 and MAP2K2, also known as MEK1 and MEK2. It is a small molecule inhibitor of these kinases. By inhibiting MAP2K1 and MAP2K2, AZD8330 interferes with the MAPK signaling pathway, which is often dysregulated in cancer.
AZD8330 is being developed by AstraZeneca PLC, a pharmaceutical company traded on the Nasdaq under the ticker AZN. AstraZeneca sponsored the Phase 1 trial of AZD8330 in patients with advanced malignancies.
AZD8330 is in Phase 1 clinical development. It has completed one Phase 1 trial, NCT00454090, which enrolled 83 patients with advanced malignancies. The trial was conducted in the United States and Norway. AZD8330 is not FDA approved.
AZD8330 has been studied in one clinical trial: NCT00454090, titled "AZD8330 First Time in Man in Patients With Advanced Malignancies." This Phase 1 trial is completed and enrolled 83 patients. It was an uncontrolled, non-randomized study conducted in the United States and Norway.